Current Landscape and Open Questions on Adjuvant Therapies in Melanoma

Melanoma is a form of skin cancer that is frequently diagnosed at early stages. In most cases, surgical resection is curative. In case of thicker melanomas (> pT1b) without clinical or instrumental evidence of metastasis, a sentinel lymph node biopsy is recommended for staging purposes. If the l...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vincenzo De Falco, Stefania Napolitano, Luigi Pio Guerrera, Teresa Troiani
Formato:	article
Lenguaje:	EN
Publicado:	Mattioli1885 2021
Materias:	stage III melanoma adjuvant therapy locoregional melanoma Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/c545f0a9288e4d2bbb4e8bfaa6efb39c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c545f0a9288e4d2bbb4e8bfaa6efb39c
record_format	dspace
spelling	oai:doaj.org-article:c545f0a9288e4d2bbb4e8bfaa6efb39c2021-11-17T08:27:38ZCurrent Landscape and Open Questions on Adjuvant Therapies in Melanoma10.5826/dpc.11S1a165S2160-9381https://doaj.org/article/c545f0a9288e4d2bbb4e8bfaa6efb39c2021-07-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1882https://doaj.org/toc/2160-9381 Melanoma is a form of skin cancer that is frequently diagnosed at early stages. In most cases, surgical resection is curative. In case of thicker melanomas (> pT1b) without clinical or instrumental evidence of metastasis, a sentinel lymph node biopsy is recommended for staging purposes. If the lymph nodes are the only site of disease (macroscopic or microscopic> 1mm), configuring stage III, the international guidelines recommend the use of adjuvant therapy with checkpoint inhibitors (nivolumab or pembrolizumab) or targeted therapies (dabrafenib plus trametinib). These drugs have shown a significant increase in recurrence-free survival, although some doubts and open questions remain. Specifically, none of the available treatments has shown a clear benefit in the overall survival rates, the advantages they give in stage IIIA are not well known, and finally there are still no prospective clinical studies identifying the best approach to continue the therapeutic process in case of relapse. Furthermore, there are new opportunities opening up with the upcoming results of the neoadjuvant trials that could revolutionize the treatment of clinically evident stage III melanoma. Vincenzo De FalcoStefania NapolitanoLuigi Pio GuerreraTeresa TroianiMattioli1885articlestage III melanomaadjuvant therapylocoregional melanomaDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 11, Iss S1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	stage III melanoma adjuvant therapy locoregional melanoma Dermatology RL1-803
spellingShingle	stage III melanoma adjuvant therapy locoregional melanoma Dermatology RL1-803 Vincenzo De Falco Stefania Napolitano Luigi Pio Guerrera Teresa Troiani Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
description	Melanoma is a form of skin cancer that is frequently diagnosed at early stages. In most cases, surgical resection is curative. In case of thicker melanomas (> pT1b) without clinical or instrumental evidence of metastasis, a sentinel lymph node biopsy is recommended for staging purposes. If the lymph nodes are the only site of disease (macroscopic or microscopic> 1mm), configuring stage III, the international guidelines recommend the use of adjuvant therapy with checkpoint inhibitors (nivolumab or pembrolizumab) or targeted therapies (dabrafenib plus trametinib). These drugs have shown a significant increase in recurrence-free survival, although some doubts and open questions remain. Specifically, none of the available treatments has shown a clear benefit in the overall survival rates, the advantages they give in stage IIIA are not well known, and finally there are still no prospective clinical studies identifying the best approach to continue the therapeutic process in case of relapse. Furthermore, there are new opportunities opening up with the upcoming results of the neoadjuvant trials that could revolutionize the treatment of clinically evident stage III melanoma.
format	article
author	Vincenzo De Falco Stefania Napolitano Luigi Pio Guerrera Teresa Troiani
author_facet	Vincenzo De Falco Stefania Napolitano Luigi Pio Guerrera Teresa Troiani
author_sort	Vincenzo De Falco
title	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
title_short	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
title_full	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
title_fullStr	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
title_full_unstemmed	Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
title_sort	current landscape and open questions on adjuvant therapies in melanoma
publisher	Mattioli1885
publishDate	2021
url	https://doaj.org/article/c545f0a9288e4d2bbb4e8bfaa6efb39c
work_keys_str_mv	AT vincenzodefalco currentlandscapeandopenquestionsonadjuvanttherapiesinmelanoma AT stefanianapolitano currentlandscapeandopenquestionsonadjuvanttherapiesinmelanoma AT luigipioguerrera currentlandscapeandopenquestionsonadjuvanttherapiesinmelanoma AT teresatroiani currentlandscapeandopenquestionsonadjuvanttherapiesinmelanoma
_version_	1718425827193913344

Current Landscape and Open Questions on Adjuvant Therapies in Melanoma

Ejemplares similares